CRISPR Therapeutics AG — Director's Dealing 2021

Jul 1, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2021-06-28

Reporting Person: Bolzon Bradley J PhD (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-28	Common Shares	S	3216	$150.6503	Disposed	17159	Direct
2021-06-28	Common Shares	S	1578	$150.6503	Disposed	167253	Indirect
2021-06-28	Common Shares	S	6403	$151.4949	Disposed	10756	Direct
2021-06-28	Common Shares	S	3144	$151.4949	Disposed	164109	Indirect
2021-06-28	Common Shares	S	3139	$152.3763	Disposed	7617	Direct
2021-06-28	Common Shares	S	1540	$152.3763	Disposed	162569	Indirect
2021-06-28	Common Shares	S	4519	$153.5389	Disposed	3098	Direct
2021-06-28	Common Shares	S	2218	$153.5389	Disposed	160351	Indirect
2021-06-28	Common Shares	S	2281	$154.5656	Disposed	817	Direct
2021-06-28	Common Shares	S	1119	$154.5656	Disposed	159232	Indirect
2021-06-28	Common Shares	S	268	$155.2725	Disposed	549	Direct
2021-06-28	Common Shares	S	132	$155.2725	Disposed	159100	Indirect
2021-06-28	Common Shares	S	549	$156.5414	Disposed	0	Direct
2021-06-28	Common Shares	S	269	$156.5414	Disposed	158831	Indirect

Footnotes

F1: The sale of these shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3: These Securities are held of record by Versant Venture Management, LLC ("VVM LLC"), for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person.

F4: These securities are held of record by VVM LLC, a portion of which are held for the benefit of the Reporting Person, pursuant to an agreement between VVM LLC and the Reporting Person. The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any.

F5: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.00 to $151.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.

F6: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.00 to $152.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4.

F7: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $153.02 to $153.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4.

F8: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.00 to $154.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4.

F9: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.23 to $155.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4.

F10: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.26 to $156.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4.